Century Therapeutics Inc
Century Therapeutics Inc (IPSC) Covered Calls
Century Therapeutics Inc trades in the Biotechnology industry with an IV Rank of 55.56%, average versus the past year. IPSC's highest covered call setup is the $2.50 strike expiring Apr 16, 2027, sorted by theoretical annualized return. It's 89.39% out of the money with 148 days to expiration, a 93.18% return until expiration, and a 229.81% theoretical annualized return. Across the setups shown, annualized returns run from 86.54% to 229.81% at strikes between $2.00 and $2.50, with 148 to 393 days to expiration, as of Nov 19, 2026.
Read more
Running IPSC covered calls helps you generate income from Century Therapeutics Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best IPSC covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If IPSC stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling IPSC covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given IPSC covered call is worth writing.
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma.
| 2027-04-16 | 148 | 2.50 | 89.39 | 0.05 | 1.05 | 123.00 | 93.18 | 229.81 | -3.79 | +0.64 | 335 | 1.00 |
| 2027-04-16 | 148 | 2.00 | 51.52 | 0.05 | 0.70 | 73.00 | 55.30 | 136.39 | -3.79 | +0.56 | 121 | 0.65 |
| 2027-12-17 | 393 | 2.50 | 89.39 | 0.05 | 1.05 | 123.00 | 93.18 | 86.54 | -3.79 | +0.64 | 1 | 1.00 |
As of Nov 19, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank55.56% Moderate
- Market cap (M$)212
- 52 weeks high-61.84%
- 52 weeks low152.17%
- Analyst recommendationStrong Buy
1.33 - Target price$5.12
341.38% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-12
- P/E—
- Future P/E—
- EPS (ttm)-0.61
- EPS growth next 5 years—
As of Nov 20, 2026